Urologix Inc  

(Public, OTCMKTS:ULGX)   Watch this stock  
Find more results for ULGX
0.150
+0.001 (0.67%)
Apr 16 - Close
OTCMKTS data delayed by 15 mins - Disclaimer
Currency in USD
Range 0.13 - 0.15
52 week 0.11 - 0.53
Open 0.15
Vol / Avg. 40,751.00/25,471.00
Mkt cap 3.20M
P/E     -
Div/yield     -
EPS -0.22
Shares 21.33M
Beta 1.59
Inst. own 35%
May 6, 2014
Q3 2014 Urologix, Inc. Earnings Conference Call - 5:00PM EDT - Add to calendar
May 6, 2014
Q3 2014 Urologix, Inc. Earnings Release - 4:00PM EDT - Add to calendar
Feb 4, 2014
Q2 2014 Urologix, Inc. Earnings Conference Call - Webcast
Feb 4, 2014
Q2 2014 Urologix, Inc. Earnings Release
  

Key stats and ratios

Q4 (Dec '13) 2013
Net profit margin -28.51% -25.87%
Operating margin -23.44% -22.40%
EBITD margin - -18.61%
Return on average assets -38.32% -34.06%
Return on average equity - -820.65%
Employees 95 -
CDP Score - -

Address

14405 21ST AVE N
MINNEAPOLIS, MN 55447
United States - Map
+1-612-4751400 (Phone)
+1-763-4048118 (Fax)

Website links

Description

Urologix, Inc. (Urologix) develops, manufactures, and markets non-surgical, office-based therapies for the treatment of the symptoms and obstruction resulting from non-cancerous prostate enlargement also known as benign prostatic hyperplasia (BPH). These therapies use technology in the treatment of BPH, a disease that affects more than 30 million men worldwide and is the most common prostate problem for men over 50. It markets both the Cooled ThermoTherapy (CTT) product line and the Prostiva Radio Frequency (RF) Therapy System. The Prostiva RF Therapy System delivers radio frequency energy directly into the prostate through the use of insulated electrodes deployed from a transurethral scope, ablating targeted prostatic tissue under the direct visualization of the urologist. These focal ablations reduce constriction of the urethra, thereby relieving BPH voiding symptoms. It acquired the worldwide license to the Prostiva RF Therapy System, in September 2011.

Officers and directors

Gregory J. Fluet Chief Executive Officer, Director
Age: 44
Brian J. Smrdel Chief Financial Officer
Age: 44
Lisa A. Ackermann Executive Vice President - Sales and Marketing
Age: 41
Mitchell Dann Independent Non-Executive Chairman of the Board, Lead Director
Age: 53
Christopher R. Barys Independent Director
Age: 47
Sidney W. Emery Jr. Independent Director
Age: 67
Patrick D. Spangler Independent Director
Age: 58